Drug Trial Radar · NCT03015311
Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients
Last checked: Nov 19, 2026Latest source record: Jul 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
8,000
Planned (sponsor's estimate)
Start
Jan 15, 2017
Primary completion
Dec 31, 2020
Study completion Dec 31, 2021
Sponsor
- Lead sponsor
- Chinese Academy of Medical Sciences, Fuwai HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 10, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 60 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients (STEP) is a 2-arm, multi-center, prospective, randomized, open-labeled, blinded-endpoint trial. The purpose of this trial is to test whether a treatment program aimed at reducing systolic blood pressure (SBP) to a lower goal (\<130 mmHg, intensive treatment) than currently recommended (\<150 mmHg, standard treatment) will reduce CVD risk among persons between 60-80 years of old. Furthermore, this trial will also examine the effect of blood pressure APP management strategy via WeChat network on medication compliance, blood pressure control and CVD benefits.
Conditions
- Primary Hypertension
Interventions
Intensive BP controlDrug
For all participants, Olmesartan Medoxomil tablets or Amlodipine Besylate tablets will be used as an initial therapy. Other drugs, including hydrochlorothiazide and β-blockers, are allowed, in order to achieve the SBP target. If the target BP level is not achieved during the Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol.
Standard BP controlDrug
For all participants, Olmesartan Medoxomil tablets or Amlodipine Besylate tablets will be used as an initial therapy. Other drugs, including hydrochlorothiazide and β-blockers, are allowed, in order to achieve the SBP target. If the target BP level is not achieved during the Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary composite outcomeTime frame: 4 years
Locations
42 sites in 1 country. Site status is shown where the registry gives one.
Beijing Chaoyang Hospital affiliated to Capical Medical University
Beijing, Beijing Municipality, China
Bei Jing Hospital
Beijing, Beijing Municipality, China
Chinese Academy of Medical Sciences, FuWai Hospital
Beijing, Beijing Municipality, China
Xuanwu hospital of capital medical university
Beijing, Beijing Municipality, China
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Beijing Pinggu Hospital
Beijing, Beijing Municipality, China
Lanzhou University Second Hospital
Lanzhou, Gansu, China
Guangdong Cardiovascular Institute
Guangzhou, Guangdong, China
Huizhou Municipal Central Hospital
Huizhou, Guangdong, China
The Second Affiliated Hospital to Medical College Shantou University Guangdong
Shantou, Guangdong, China
Shenzhen Sun Yat-sen Cardiovascular Hospital
Shenzhen, Guangdong, China
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China
The First Affiliated Hospital of Guangxi University of Chinese Medicine
Nanning, Guangxi, China
Kailua General Hospital
Tangshan, Hebei, China
The First Affiliated Hospital of Hebei North University
Zhangjiakou, Hebei, China
First affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Hong xinglong center hospital
Shuangyashan, Heilongjiang, China
First Affiliated Hospitalof Zhengzhou University
Zhengzhou, Henan, China
Zhoukou City Central Hospital
Zhoukou, Henan, China
Renmin Hospital of Wuhan University
Wuhan, Hubei, China
Kang Ya Hospita
Yiyang, Hunan, China
The Second Affiliated Hospital of Baotou Medical College
Baotou, Inner Mongolia, China
Zhenjiang First People's Hospital
Zhenjiang, Jiangsu, China
the Second Affiliated Hospitalof NanChang University
Nanchang, Jiangxi, China
Benxi Railway Hospital
Benxi, Liaoning, China
The 1st Affiliated Hospital of Dalian Medical University
Dalian, Liaoning, China
The First People's Hospital of Yinchuan
Yinchuan, Ningxia, China
Qilu Hospital of Shandong University
Jinan, Shandong, China
Jining First People's Hospital
Jining, Shandong, China
Shanghai general hospital, Shanghai Jiaotong University
Shanghai, Shanghai Municipality, China
First Hospital of Shanxi Medical University
Taiyuan, Shanxi, China
Shanxi caidiovascular hospital
Taiyuan, Shanxi, China
Shanxi Academy of Medical Sciences, Shanxi Dayi Hospital
Taiyuan, Shanxi, China
First Affiliated Hospital, Xian Jiaotong University
Xi’an, Shanxi, China
West China Hospital, Sichuan University
Chengdu, Sichuan, China
College of Medicine , National Taiwan University
Taibei, Taiwan, China
Pingjin Hospital, Logistics University of PAPF
Tianjin, Tianjin Municipality, China
the People's Hospital of Ji Xian Distric
Tianjin, Tianjin Municipality, China
First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China
Yan'an Hospital affiliated to kunming medical university, Yunnan Cardiovascular Hospital
Kunming, Yunnan, China
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.